Insulet Co. (NASDAQ:PODD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Insulet Co. (NASDAQ:PODD) has received an average rating of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $269.40.

A number of research firms have issued reports on PODD. Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Raymond James lifted their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Wells Fargo & Company boosted their target price on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. grew its stake in Insulet by 20.7% during the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after purchasing an additional 389,639 shares during the period. Geode Capital Management LLC increased its stake in shares of Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after acquiring an additional 22,850 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Insulet by 6.0% during the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after acquiring an additional 75,526 shares during the period. American Century Companies Inc. boosted its stake in Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after acquiring an additional 139,246 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the period.

Insulet Stock Down 0.0 %

NASDAQ PODD opened at $263.23 on Thursday. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The business has a fifty day moving average price of $256.41 and a two-hundred day moving average price of $224.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.46 billion, a PE ratio of 45.07, a PEG ratio of 4.12 and a beta of 1.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.